Podcasts / Using SGLT2 to reduce cardiovascular death in T2D – Important updates for GPs
Save
0.5 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.
Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.
82% of GPs rated this lecture as excellent
In this Healthed lecture, Professor Andrew Sindone and Dr Ted Wu discuss the importance of SGLT2 inhibitors in this space and the ground-breaking evidence that has seen this class of drugs now be recommended as second-line T2D treatment after metformin, particularly for its cardiovascular benefits. Importantly, the experts will also explain recent PBS changes that have improved access to SGLT2 inhibitors as well as other practical considerations associated with these medications.
Vision and Driving Fitness: Key Insights for Health Practitioners
Role of Testosterone During Menopause – Evidence vs Hype
STIs – Common and Tricky Cases
RSV Prevention in Infants and Pregnant Women
Browse the latest podcasts from Healthed.
You have completed the Educational Activities (EA) component of this activity.
Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.
You will be taken to explore further CPD learning available to you.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease